Schellens, Jan H.M.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 3,634

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,491

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics

Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical Methods

Cited by 725

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 592

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

Bevacizumab

Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010) · The Oncologist

Angiogenesis and VEGF in CancerColorectal Cancer Treatments and Studies

Cited by 291

Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein)

Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 284

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 224

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

Keizer, R. J., Jansen, R. S., Rosing, H., Thijssen, B., Beijnen, J. H., Schellens, J. H. M., & Huitema, A. D. R. (2015) · Pharmacology Research & Perspectives

Pharmaceutical studies and practicesStatistical Methods in Clinical Trials

Cited by 200

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 181

Fixed Dosing of Monoclonal Antibodies in Oncology

Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist

Monoclonal and Polyclonal Antibodies ResearchPharmaceutical studies and practices

Cited by 168

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF -Mutant Colorectal Cancer

Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 121

Lapatinib for Advanced or Metastatic Breast Cancer

Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012) · The Oncologist

HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology

Cited by 113

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., et al. (2016) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 73

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., & Wilmink, J. W. (2015) · Cancer Chemotherapy and Pharmacology

Pancreatic and Hepatic Oncology ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 71

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 71

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer

Cancer-related Molecular PathwaysMelanoma and MAPK Pathways

Cited by 62

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 55

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

Brummelen, E. M. J., Huijberts, S., Herpen, C., Desar, I., Opdam, F., Geel, R., Marchetti, S., Steeghs, N., Monkhorst, K., Thijssen, B., et al. (2021) · The Oncologist

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 32

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study

Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., & Beijnen, J. H. (2015) · Therapeutic Drug Monitoring

Biosimilars and Bioanalytical MethodsPharmacogenetics and Drug Metabolism

Cited by 14

Effects of methimazole on the elimination of irinotecan

van der Bol, J. M., Visser, T. J., Loos, W. J., de Jong, F. A., Wiemer, E. A. C., van Aken, M. O., Planting, A. S., Schellens, J. H., Verweij, J., & Mathijssen, R. H. J. (2011) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismCancer therapeutics and mechanisms

Cited by 9

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium

Janssen, J. M., Zwaan, C. M., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2017) · European Journal of Cancer

Pharmaceutical studies and practicesStatistical Methods in Clinical Trials

Cited by 6